1	Genetic Evidence for Soluble VEGFR2 as a Protective Factor Against Macular Pucker
2	
3	Qi Gao ^{1*} and Jinglong Guo ^{1*}
4	
5	1 Department of Cardiovascular Diseases, the First Hospital of Jilin University, Changchun
6	130021, China
7	
8	* Correspondence:
9	Jinglong Guo: guojl14@mails.jlu.edu.cn
10	Qi Gao: gaoqi2019@jlu.edu.cn
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	

It is made available under a CC-BY-NC-ND 4.0 International license .

24 Abstract

Background: Identifying factors that protect against macular pucker (MP) is crucial for
developing effective treatments. We hypothesize that soluble vascular endothelial growth factor
receptor 2 (sVEGFR2), a decoy receptor for VEGF signaling, may provide such protection.
Methods: We performed a genome-wide association (GWAS) meta-analysis on three
independent studies of sVEGFR2 protein quantitative trait loci (pQTL), which was used to

31 identify novel variants and select variants strongly associated with sVEGFR2 levels. We

32 investigated the association between sVEGFR2 levels and the risk of MP using *cis*-Mendelian

33 Randomization (cis-MR) and Bayesian colocalization. We also used the UKB-PPP study of

34 sVEGFR2 pQTL, which used a different method for measuring plasma protein, to validate the

35 results from *cis*-MR and colocalization.

36

37 **Results**: GWAS meta-analysis identified four novel variants associated with sVEGFR2 levels, 38 rs9411335 (MED27), rs6992534 (ERII), rs11893824 (LIMS2), and rs7678559 (PCDH7). Cis-39 MR analysis suggested that higher levels of sVEGFR2, genetically predicted using the meta-40 analysis dataset, were associated with a lower risk of MP (OR 0.86, 95% CI 0.77-0.95, $P = 4.6 \times$ 41 10⁻³). Colocalization supported shared genetic variants in the VEGFR2 gene region between 42 sVEGFR2 and MP (PPH4 = 0.92). Using sVEGFR2 pQTL from UKB-PPP study, sVEGFR2's 43 inverse association with MP was validated by cis-MR (OR 0.86, 95% CI 0.78-0.96, $P = 4.4 \times 10^{-10}$ 44 ³) and colocalization (PPH4 = 0.95). Sensitivity analyses showed no evidence of pleiotropy or 45 reverse causality, though some heterogeneity was found.

It is made available under a CC-BY-NC-ND 4.0 International license .

- **Conclusions**: Our study suggested that sVEGFR2 has a protective effect against MP and could
- 48 be a potential therapeutic target. Further research is necessary to elucidate its protective
- 49 mechanisms and validate its translational implications.
- 51 Keywords: soluble VEGFR2, macular pucker, causally protective effects, GWAS meta-analysis,
- 52 cis-Mendelian Randomization, Bayesian colocalization

It is made available under a CC-BY-NC-ND 4.0 International license .

70 Background

71 Macular pucker (MP), also known as epiretinal membrane, is a potentially sight-threatening 72 vitreoretinal disease. It is characterized by a sheet of abnormal, thin, fibrotic tissue that grows on 73 the surface of the macula that is responsible for detailed central vision. The prevalence of MP 74 ranges from 7% to 11.8%, with aging being the primary nonmodifiable risk factor. Surgical 75 intervention, such as vitrectomy with membrane peeling, is the current standard of care for 76 symptomatic MP cases (1-3). However, pharmacological approaches targeting MP pathogenesis 77 are still largely lacking, likely due to an insufficient understanding of the causal factors involved 78 (1-3).

79

The MP pathogenesis involves a complex interplay among various cells and acellular factors, 80 81 including angiogenesis, inflammation, and fibrosis at the vitreoretinal interface (4-6). VEGFR2 82 is expressed in retinal pigment epithelium and endothelial cells within MP tissues, indicating its 83 potential role in the disease's pathogenesis (7-9). VEGFR2 signaling, which is activated through 84 the binding of VEGF-A, promotes crucial processes in endothelial cells of blood vessels such as 85 proliferation, migration, and survival (10). In addition, VEGFR2 signaling is also implicated in 86 fibrosis and inflammation (11). Of note, soluble forms of VEGFR2 (sVEGFR2) can regulate 87 VEGFR2 signaling by acting as decoy receptors for VEGF-A (12-14). In mice, sVEGFR2 has 88 been shown to suppress corneal neovascularization and lymphangiogenesis (15). In humans, 89 sVEGFR2 has been suggested to play an important role in macular edema through regulating 90 angiogenesis (16, 17). Despite this, the causal relationships between sVEGFR2 and human 91 retinal diseases such as MP remain not inferred.

It is made available under a CC-BY-NC-ND 4.0 International license .

93	Mendelian randomization (MR) is a method used to evaluate the potential causality of a
94	modifiable exposure on an outcome by utilizing genetic variants as instrumental variables (18).
95	Because genetic variants are randomly assorted during gamete formation and fixed at
96	conception, MR estimates could minimize bias resulting from confounding factors or reverse
97	causality. Cis-MR specifically refers to MR studies that use genetic variants from gene-restricted
98	regions of pharmacological protein of interest, and it is typically employed for drug target
99	validation (19). Bayesian colocalization analysis evaluates whether two distinct traits are affected
100	by the same causal variants, making it an important complementary analysis to appraise the
101	validity and strength of a cis-MR estimate (20). Meta-analysis of independent genome-wide
102	association studies (GWAS) combines data from multiple studies into a single, large-scale dataset
103	(21). This approach not only helps in discovering new genetic variants but also enhances the
104	reliability and robustness of results when used in MR and colocalization studies (22). Using
105	these advanced genetic methodologies, we investigated the relationship between plasma levels of
106	sVEGFR2 and MP risk.
107	
108	Methods
109	Data source
110	Information of the data sources used in this study was summarized in Supplementary table 1. The
111	study relied on summary-level GWAS data that have been available publicly, ethical approvals

112 were obtained in all original studies. sVEGFR2 pQTL used for meta-analysis included Interval

study, with 3,301 Europeans (23); AGES study, with 5,361 Icelanders (24); and DECODE study,

114 with 35,559 Icelanders (25). The plasma protein in these studies were measured by SomaScan

115 platform. In addition, sVEGFR2 pQTL from the UK Biobank Pharma Proteomics Project (UKB-

It is made available under a CC-BY-NC-ND 4.0 International license .

PPP) study (plasma protein measured by Olink and included 33,822 UK participants) was also
used (26). In the original study, plasma proteins were measured with standard quality controls
and adjusted for year of birth, sex, and year of sample collection. GWAS of MP (N=4,599 cases,
N=413,784 controls) and other macula conditions were from the 11th release of FinnGen study,
with cases being defined based on International Classification of Diseases (ICD-10). The original
GWAS of eye diseases in the FinnGen study were adjusted for age, sex, and genetic principal
components (27).

123

124 Genome-wide association studies of sVEGFR2 pQTL

125 We performed a meta-analysis on plasma sVEGFR2 pQTL using data from three independent 126 studies Interval, AGES, and DECODE. To account for potential heterogeneity in genetic 127 associations, due to difference participants and/or environment, we performed the meta-analysis 128 of random effects using METAL (version 2011-02-25) (28). This comprehensive analysis 129 resulted in a dataset of 44,221 individuals and over 25 million variants. The base pair positions in 130 original Interval and AGES studies were based on GRCh37, which were transformed to GRCh38 131 using LiftOver (version 1.28.0) (29). Finally, all the datasets used in the studies were based 132 GRCh38. Unsing PLINK 2.00 alpha (30), independent lead genetic variants were identified by 133 filtering associations on a genome-wide significant P-value of 5×10^{-8} and clumping to a R² of 134 0.001 with 10000kb window based on the European 1000 Genome Project reference panel. The 135 nearest protein-coding genes were identified using Open Targets, with CADD scored evaluated 136 (31). Combined Annotation-Dependent Depletion (CADD) has been widely used to predict the 137 deleteriousness of variants throughout the human genome (32). Novel variants were identified by 138 excluding variants that located within 500kb of loci in original studies (Interval, AGES, and

It is made available under a CC-BY-NC-ND 4.0 International license .

- DECODE) and variants of genome-wide significant in the sVEGFR2 pQTL of UKB-PPP study(Supplementary table 2).
- 141

142 Selection of genetic instruments

- 143 All above mentioned datasets of sVEGFR2 pQTL (namely Internal, AGES, DECODE, Meta-
- analysis, and UKB-PPP study) were used to select genetic instruments for sVEGFR2. Genetic
- 145 variants associated with sVEGFR2 with genome-wide significance and located \pm 100 kilobase
- 146 (kb) of *VEGFR2* gene (chromosome 4, GRCh38 position 55078481-55125595) were selected.
- 147 These variants were then pruned to remove SNPs in high linkage disequilibrium ($R^2 < 0.1$)
- 148 within a 100kb window based on the 1000 Genomics European reference panel. To select
- 149 variants associated with MP, a GWAS-correlated P-value $< 5 \times 10^{-8}$ and linkage disequilibrium
- 150 (LD) $R^2 < 0.001$ within a 10,000kb window based on the European 1000 Genome Project
- 151 reference panel. Variants with F-statistic < 10 and minor allele frequency (MAF) < 0.01 were
- 152 excluded. F-statistic > 10 indicates robust instrument strength, calculated by $F = R^2 (N K K)$
- 153 1)/K(1 R^2), where R^2 is the proportion of variance in the exposure explained by genetic
- 154 variants, K is the number of instruments, and N is the sample size. R² estimates the proportion of
- 155 variance in the phenotype explained by the genetic variant,
- 156 $R^2 = 2 \times (Beta/SD)^2 \times (MAF) \times (1 MAF)$, where Beta represents the per-allele effect size of the 157 association between each variant and the phenotype, and SD denotes the standard deviation (33).
- 158 Detailed information on the genetic variants was provided in Supplementary table 3.

159

160 *cis*-MR analysis

It is made available under a CC-BY-NC-ND 4.0 International license .

161 We performed MR analyses following the STROBE-MR guidelines (34). MR study should be 162 conducted based on three core principles: (1) relevance, the genetic instruments should be 163 significantly associated with the exposure; (2) independence, the genetic instruments should not 164 be associated with any potential confounder and (3) exclusion restriction, the genetic instruments 165 should not directly affect the outcome except via the way of exposure (18). Genetic correlations 166 between exposure and outcome for each variant were harmonized by aligning effects alleles, 167 with exclusion of palindromic variants. Prior to each MR analysis, MR Pleiotropy RESidual Sum 168 and Outlier (MR-PRESSO) was applied to identify and remove potential outliers (35). The 169 causal effects were assessed mainly using inverse variance-weighted (IVW) method of MR (36). 170 This method assumes that outcomes are influenced only by the exposure, setting the intercept at 171 zero (36). We also performed MR Egger, which allows sensitivity tests to rule out potential bias 172 induced by horizontal pleiotropy using the inclusion of the intercept in the regression analysis, 173 and P < 0.05 was considered significant for the presence of horizontal pleiotropy (37). MR-174 PRESSO global test was used to assess the presence of horizontal pleiotropy and P value < 0.05175 was considered significant for the presence of horizontal pleiotropy (35). The Cochran's Q test 176 was used to assess heterogeneity, and $P \le 0.05$ was considered significant for the presence of 177 heterogeneity (38). The leave-one-out plots were used to assess the influence of individual 178 variants on observed associations (38). The MR Steiger directionality tests were used to assess 179 whether there was reverse causality in our *cis*-MR study (39). Reverse MR with IVW method 180 aimed to evaluate whether MP was causally associated with sVEGFR2 levels and was employed. 181 No proxy variants were used across the MR analyses.

182

183 Bayesian colocalization analysis

It is made available under a CC-BY-NC-ND 4.0 International license .

184	Bayesian colocalization was performed to investigate whether sVEGFR2 and MP shared genetic
185	variants within ± 100 kb around the <i>VEGFR2</i> gene. The "coloc" package (version 5.2.3) in R
186	(version 4.4.1) was utilized for these analyses (40), with visualization facilitated by the
187	"locuscomparer" package (version 1.0.0) (41). The posterior probability of hypothesis 4
188	(PPH4) > 0.8 indicated strong evidence of colocalization.
189	
190	Statistical analysis
191	The IVW method was used to assess the causal effect. MR results were reported as odds ratios
192	(OR) with 95% confidence interval (CI) per one-SD increase in log-transformed unit of
193	sVEGFR2 levels. All MR analyses were two-sided and performed using package
194	'TwoSampleMR' (version 0.6.4) in R (version 4.4.1). $P < 0.05$ was considered statistically
195	significant.
196	
197	Results
198	Discovery of novel sVEGFR2-associated variants through genome-wide association meta-
199	analysis
200	The overall study design was shown in Figure 1. Our meta-analysis on sVEGFR2 pQTL of
201	Interval, AGES, and DECODE studies identified 30 independent variants with genome-wide
202	significance. We mapped their corresponding genes and searched their CADD scores using Open
203	Targets (31). Among these, six variants were considered novel, as they located outside the ± 500
204	kb window of known loci identified in the original studies (Interval, AGES, and DECODE).
205	After further excluding variants with genome-wide significance found in the UKB-PPP study,
206	which included 33822 European individuals with over 20 million variants and used Olink

- 207 technology for plasma protein measurement (26), four novel variants remained. Specifically,
- these were rs9411335 (MED27, Mediator Complex Subunit 27), rs6992534 (ERI1,
- 209 Exoribonuclease 1), rs11893824 (LIMS2, LIM Zinc Finger Domain Containing 2), and
- 210 rs7678559 (*PCDH7*, Protocadherin 7) (Table 1 and Supplementary figure 1).

Table 1 Variants reported for plasma levels of sVEGFR2 in the meta-analysis of Interval, AGES, and DECODE datasets

SNP	CH R	POS (hg38)	Nearest gene	D score	EA	NEA	EAF	BET A	SE	Р	Directi on
Novel varia	nts										
rs9411335	9	13202583 7	MED27	0.754	a	g	0.687 6	- 0.042 9	0.007 8	4.48E- 08	
rs6992534	8	8949289	ERI1	0.05	a	с	0.300 2	- 0.043 7	0.007 9	2.71E- 08	
rs1189382 4	2	12768113 5	LIMS2	6.02	a	g	0.374 1	- 0.052 1	0.008 2	1.87E- 10	
rs7678559	4	30829441	PCDH7	0.015	t	с	0.609 7	- 0.047 1	0.008	4.13E- 09	
Previously r	eported	l variants									
rs6180416 4	1	16165323 5	FCGR2B	3.41	c	g	0.770 3	- 0.066 9	0.010 1	4.00E- 11	-?-
rs6183029 1	1	22082780 0	MTARC1	13.2	a	c	0.284 6	0.079 1	0.011 8	2.37E- 11	+++
rs1249383 0	3	98687950	ST3GAL6	2.23	t	c	0.457 3	0.164 3	0.007 2	7.33E- 114	+++
rs3423103 7	4	55106779	KDR	24.4	a	g	0.274 5	0.929 7	0.023 1	1.12E- 352	+++
rs2305948	4	55113391	KDR	23.3	t	c	0.705 9	0.354	0.014	6.46E- 142	+++
rs6229773 1	4	53788196	LNX1	3.41	t	c	0.745 9	- 0.127 8	0.021 3	2.06E- 09	+
rs3529734 3	4	57096955	IGFBP7	7.38	t	с	0.262 3	- 0.085 6	0.013 9	6.88E- 10	
rs6823788	4	55669371	NMU	1.77	a	t	0.550 8	0.064 8	$0.007 \\ 4$	2.76E- 18	+++
rs5784903 2	4	47246080	COMMD 8	N/A	ссс	ссссс	0.003 2	0.403 8	0.072 5	2.59E- 08	+??
rs1126253 34	6	31505576	MICB	0.153	t	с	0.004 9	0.363 5	0.062 6	6.28E- 09	+??
rs1875701 81	6	32196810	GPSM3	8.84	t	c	0.768 3	0.106 6	0.015 4	4.45E- 12	++-
rs8192585	6	32221046	NOTCH4	0.046	a	g	0.757 6	0.163 5	0.017 4	5.69E- 21	+++
rs932589	6	13676200 0	MAP3K5	7.23	t	с	0.561 7	- 0.048 5	0.007 4	5.25E- 11	
rs3578370 4	8	10495403 0	ZFPM2	16.6	a	g	0.704	0.060 5	0.010 5	9.44E- 09	+++
rs600038	9	13327635 4	ABO	7.6	t	с	0.843 8	0.440 6	0.007 8	3.18E- 688	+++
rs1467981 34	9	13290803 8	AK8	1.15	aattgtgccactg ca	aattgtgccactg cg	0.017 7	0.315 3	0.031 6	2.04E- 23	+??
rs3124774	9	13349638 1	SLC2A6	0.912	tgcatacacgca	tgcatacacgcg	0.392 1	0.066 3	0.008 6	9.95E- 15	+??

medRxiv preprint doi: https://doi.org/10.1101/2024.11.29.24318222; this version posted November 30, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

rs1176080 58	9	13354028 2	ADAMTS L2	7.32	a	g	0.976 3	- 0.191 1	0.026 6	6.20E- 13	-??
rs1160312 3	11	12643560 0	ST3GAL4	15.4	a	g	0.766 8	0.288 4	0.018 7	2.03E- 53	+++
rs1176031 93	11	12639096 9	ST3GAL4	5.53	a	g	0.237 9	0.212 1	0.028 7	1.51E- 13	+++
rs1125648 08	11	12617729 5	RPUSD4	1.81	t	с	0.209 2	- 0.173 6	0.026 6	6.66E- 11	
rs1280828 5	11	95449298	SESN3	0.497	t	g	0.715 9	0.088 6	0.013 4	3.83E- 11	+++
rs1064912 2	12	57256822	STAC3	5.58	ct	ctctct	0.265 3	0.051 8	0.009 3	2.17E- 08	+??
rs704	17	28367840	SEBOX	0.199	а	g	0.504 5	-0.052	0.007 2	4.60E- 13	
rs6110213 5	17	83072806	METRNL	4.48	g	ga	0.145 7	0.089 3	0.014 5	7.72E- 10	+?+
rs1435017 83	17	7897001	NAA38	3.12	t	c	0.086 6	- 0.214 2	0.035 9	2.40E- 09	-?-

SNP, single nucleotide polymorphism; CHR, chromosome; POS, position; CADD, combined annotation-dependent depletion; EA, effect allele; NEA, other allele; EAF, effect allele frequency

211

212 **3.2** *Cis*-MR and colocalization suggested sVEGFR2 as a protective factor against MP

213 Cis-MR analysis using IVW method indicated that genetically predicted higher levels of

svEGFR2 were associated with a reduced risk of MP (Figure 2). Specifically, for svEGFR2

215 levels inferred from genetic variants in the meta-analysis, the odds ratio (OR) for MP was 0.86

216 (95% CI: 0.77-0.95, $P = 4.6 \times 10^{-3}$), while for sVEGFR2 levels inferred from the UKB-PPP

study, the OR was 0.86 (95% CI: 0.78-0.96, $P = 4.4 \times 10^{-3}$). Additionally, sVEGFR2 levels

218 predicted by genetic variants from the Interval and DECODE studies, but not the AGES study,

also showed an inverse association with MP (Figure 2 and Supplementary figure 2).

220

221 To validate these findings, we conducted Bayesian colocalization analyses (Figure 3). The results

revealed that the *VEGFR2* gene region was shared between sVEGFR2 pQTL and MP across all

analyses. The PPH4 was as follows: 0.93 for the Interval study, 0.93 for the AGES study, 0.92 for

the DECODE study, 0.92 for the meta-analysis, and 0.95 for the UKB-PPP study (Figure 3).

225

226 Tests for sensitivity and reverse causality

It is made available under a CC-BY-NC-ND 4.0 International license .

227	To ensure the robustness of our findings, we conducted a series of rigorous sensitivity analyses in
228	our cis-MR study to examine the relationship between sVEGFR2 levels and MP risk. We
229	employed MR-Egger intercept and MR-PRESSO global tests to assess horizontal pleiotropy.
230	Both tests consistently showed no evidence of horizontal pleiotropy across all examined
231	associations (Supplementary table 4). However, Cochran's Q tests revealed significant
232	heterogeneity between sVEGFR2 levels in the meta-analysis and the UKB-PPP study, and the
233	outcome in our cis-MR analyses (Supplementary table 4). Despite this, the heterogeneity was
234	deemed acceptable given that our primary cis-MR results were estimated using the IVW method.
235	Additionally, leave-one-out plots suggested that no single genetic variant disproportionately
236	influenced the overall results of our cis-MR study (Supplementary figure 3).
237	
238	To address the potential for reverse causality, we performed MR Steiger directionality tests,
239	which provided no evidence of reverse causation in the significant cis-MR results
240	(Supplementary table 5). Further, we conducted reverse MR analyses, treating MP as the
241	exposure and sVEGFR2 levels as the outcome. These analyses revealed that only the DECODE
242	study and the meta-analysis contained genetically valid variants that also intersected with MP
243	(Supplementary table 6). Importantly, no association between MP and sVEGFR2 levels was
244	found, reinforcing the absence of reverse causality in our initial cis-MR findings (Supplementary
245	table 6).
246	
247	Discussion

248 We presented a large-scale GWAS meta-analysis of SomaLogic values for plasma sVEGFR2,

249 which enabled the discovery of four novel variants associated with sVEGFR2. This meta-

It is made available under a CC-BY-NC-ND 4.0 International license .

250 analysis, along with an independent dataset for sVEGFR2 pQTL (measured by Olink) in the 251 UKB-PPP study, further enabled MR analysis sourcing cis-variants within and around the 252 VEGFR2 gene to explore potential associations between sVEGFR2 and MP. Furthermore, the 253 cis-MR results were supported by Bayesian colocalization analyses, showing the presence of 254 shared genetic variants between sVEGFR2 and MP. To the best of our knowledge, our study 255 provided the first human causal evidence that higher sVEGFR2 levels were associated with a 256 reduced risk of MP. Therefore, these analyses proposed sVEGFR2 as a promising target for 257 preventing or treating MP.

258

259 VEGFR2, a receptor primarily known for its role in endothelial cells, is also expressed in the 260 retinal pigment epithelium (RPE) (7-9). RPE is a crucial monolayer located between the 261 neuroretina and choroid and is implicated in the pathogenesis of MP (42). Dysregulation of 262 VEGFR2 signaling in the RPE can lead to aberrant endoplasmic reticulum stress, oxidative 263 stress, and inflammatory responses (43), all of which could be critical factors in MP 264 development. Abnormal blood vessel formation is also observed in vascular MP, highlighting the 265 significance of VEGFR2's functions beyond its canonical roles in endothelial cells. VEGFR2's 266 traditional functions in endothelial cells include regulating blood vessel formation and 267 permeability (10). These functions may also influence MP pathogenesis in the retina. The 268 protective role of sVEGFR2 in MP is likely multifaceted. As a decoy receptor, sVEGFR2 binds VEGF-A, competing with membrane-bound VEGFR2 (mVEGFR2) (12). This interaction can 269 270 modulate downstream processes such as angiogenesis, lymphangiogenesis, inflammation, and 271 fibrotic responses in the macula (11), potentially preventing or alleviating MP progression. By 272 sequestering VEGF-A, sVEGFR2 can also mitigate VEGF-A/mVEGFR2-mediated vascular

It is made available under a CC-BY-NC-ND 4.0 International license .

- 273 permeability, contributing to retinal vasculature stabilization and potentially reducing MP
- 274 pathogenesis (10). Further research is essential to fully elucidate sVEGFR2's protective
- 275 mechanisms in MP and to explore its potential therapeutic applications.
- 276
- 277 In addition, the meta-analysis identified four novel genetic variants associated with sVEGFR2:
- rs9411335 (MED27, Mediator Complex Subunit 27), rs6992534 (ERI1, Exoribonuclease 1),

rs11893824 (LIMS2, LIM Zinc Finger Domain Containing 2), and rs7678559 (PCDH7,

280 Protocadherin 7). Searches in the GWAS catalog did not reveal any studies linking these variants

to sVEGFR2 or mVEGFR2. Moreover, the relationship between mVEGFR2, which is expressed

on the cell surface, and the levels of sVEGFR2 secreted into circulation remains poorly

283 understood. Further investigation of these variants could reveal important regulation mechanisms

of VEGFR2 signaling and related diseases.

285

286 It has been observed that MP can be linked to various macular conditions (2). To explore whether 287 sVEGFR2 might influence MP through its association with these conditions, we examined 288 whether sVEGFR2 was related to several macular disorders. Interestingly, our analysis, using 289 genetic variants identified from meta-analyses or the UKB-PPP study to predict sVEGFR2 290 levels, found no significant association with a range of macular conditions, including macular 291 hole, retinal detachments and breaks, diabetic retinopathy, retinal vascular disorders, and retinal 292 vascular occlusions (Supplementary figure 4). These findings suggested that the association 293 between sVEGFR2 and MP may be specific to MP itself, rather than being influenced by a 294 broader relationship with these other macular conditions.

295

It is made available under a CC-BY-NC-ND 4.0 International license .

296 Our study had several major strengths. We utilized a GWAS meta-analysis to generate a large-297 scale sVEGFR2 pQTL and further validated these findings with an independent large-scale 298 sVEGFR2 pQTL from the UKB-PPP study. These studies represent plasma protein 299 measurements obtained via SomaScan and Olink, respectively. The integration of these two 300 datasets not only maximized the inclusion of genetic variants associated with sVEGFR2 but also 301 significantly improved the robustness and reliability of our findings by complementing each 302 other. Additionally, genetic variants were selected from regions \pm 100kb of VEGFR2 gene. These 303 variants were likely to have a significant impact on protein expression compared to their impact 304 on other traits. Therefore, cis-MR was less likely to violate the assumption of 'no horizontal 305 pleiotropy'. Besides, utilizing *cis*-MR for protein risk factors could enhance the reliability of 306 causal inferences by aligning with Crick's central dogma. This principle could support a 307 sequential flow from gene to protein to disease, which could be more plausible than a gene to 308 disease to protein pathway, particularly in studies using population-based samples. Therefore, 309 cis-MR could effectively minimize the likelihood of reverse causality. Furthermore, Bayesian 310 colocalization analysis is a powerful method used to determine whether two different traits or 311 genomic signals are influenced by the same causal genetic variants. Integrating *cis*-MR with 312 colocalization could synergistically harness their respective strengths, reinforcing the causal 313 relationship between sVEGFR2 and MP.

314

To appreciably understand the results, several limitations in the study should be discussed. While we identified genetic variants significantly associated with sVEGFR2 levels, they explained only a small proportion of the total variance and should not be considered as exact proxies of the exposure. Moreover, MR effect estimates assume lifelong exposure to altered protein levels (e.g.,

319	sVEGFR2)	, which could potentially be diverging from observational associations and						
320	therapeutic	interventions. Besides, sVEGFR2 levels measured in plasma from the published						
321	GWAS pQ7	TL analysis may not accurately represent their concentrations or biological functions						
322	in retinal tis	ssues, where they could potentially play a pivotal role in MP pathogenesis. This						
323	indicated th	e need for cautious interpretation of our findings. Our study primarily highlighted the						
324	causally protective effects of sVEGFR2 on MP, yet the underlying biological mechanisms							
325	require further investigation. Lastly, our study included only individuals of European descent,							
326	which could	d limit the generalizability to other populations.						
327								
328	Conclusion	l						
329	In conclusion, our study employed GWAS meta-analysis of sVEGFR2 pQTL and utilized cis-							
330	MR and colocalization analyses to provide robust genetic evidence supporting a protective effect							
331	of sVEGFR2 against MP. These findings suggested sVEGFR2 as a promising drug target for MP							
332	and warrant	ted future basic and translational research in this area.						
333								
334	List of abb	reviations						
335	MP	macular pucker						
336	sVEGFR2	soluble vascular endothelial growth factor receptor 2						
337	mVEGFR2	2 membrane-bound VEGFR2						
338	GWAS	genome-wide association studies						
339	pQTL	protein quantitative trait loci						
340	MR	mendelian randomization						
341	IVW	inverse variance weighted						

It is made available under a CC-BY-NC-ND 4.0 International license .

342	MED27	mediator complex subunit 27

- 343 ERI1 exoribonuclease 1
- 344 LIMS2 LIM zinc finger domain containing 2
- 345 PCDH7 protocadherin 7
- 346 UKB-PPP UK Biobank Pharma Proteomics Project
- 347 CADD combined annotation-dependent depletion
- 348
- 349 Ethical statement
- 350 In this study, we utilized publicly available GWAS data and ethical approvals were obtained in
- all original studies.
- 352

353 Competing interest

- 354 The authors declare no competing financial interests.
- 355

356 Funding

357 No funding source was applied to this study.

358

359 Author contributions

- 360 Study design: J.G., Q.G.; data acquisition and analysis: J.G., Q.G.; figures, tables and original
- 361 draft: J.G.; writing, reviewing and editing: J.G., Q.G.

362

363 Data sharing statement

It is made available under a CC-BY-NC-ND 4.0 International license .

- 364 All GWAS data are publicly available and described in the data source section and
- 365 supplementary table 1.
- 366

367 Supplementary materials

- 368 Supplementary materials associated with this article can be found in the online version, at xxx.
- 369

370 References

- 1. Kanukollu VM, Agarwal P. Epiretinal Membrane. StatPearls [Internet]. 2023.
- 2. Fung AT, Galvin J, Tran T. Epiretinal membrane: a review. Clinical & Experimental
- 373 Ophthalmology. 2021;49(3):289-308.
- 374 3. Steinkerchner MS, Russell MW, Sharma N, Kumar M, Talcott KE, Singh RP. Long-Term
- 375 Visual Outcomes in Patients with Idiopathic Epiretinal Membrane Surgery. Ophthalmic Surgery,
- 376 Lasers and Imaging Retina. 2024;55(2):71-7.
- 4. Ishikura M, Muraoka Y, Nishigori N, Kogo T, Akiyama Y, Numa S, et al. Cellular
- 378 Determinants of Visual Outcomes in Eyes with Epiretinal Membrane: Insights from Adaptive
- 379 Optics Optical Coherence Tomography. Ophthalmology Science. 2024:100536.
- Joshi M, Agrawal S, Christoforidis JB. Inflammatory mechanisms of idiopathic epiretinal
 membrane formation. Mediators of inflammation. 2013;2013(1):192582.
- 382 6. Hu Z, Mao X, Chen M, Wu X, Zhu T, Liu Y, et al. Single-cell transcriptomics reveals
- 383 novel role of microglia in fibrovascular membrane of proliferative diabetic retinopathy. Diabetes.
- 384 2022;71(4):762-73.

- 385 7. Chen Y-S, Hackett SF, Schoenfeld C-L, Vinores MA, Vinores SA, Campochiaro PA.
- 386 Localisation of vascular endothelial growth factor and its receptors to cells of vascular and
- avascular epiretinal membranes. British Journal of Ophthalmology. 1997;81(10):919-26.
- 388 8. Armstrong D, Augustin AJ, Spengler R, Al-Jada A, Nickola T, Grus F, et al. Detection of
- 389 vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of
- 390 proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker.
- 391 Ophthalmologica. 1998;212(6):410-4.
- 392 9. Tsanou E, Ioachim E, Stefaniotou M, Gorezis S, Charalabopoulos K, Bagli H, et al.
- 393 Immunohistochemical study of angiogenesis and proliferative activity in epiretinal membranes.
- 394 International journal of clinical practice. 2005;59(10):1157-61.
- Cao Y, Langer R, Ferrara N. Targeting angiogenesis in oncology, ophthalmology and
 beyond. Nature Reviews Drug Discovery. 2023;22(6):476-95.
- 397 11. Jeong J-H, Ojha U, Lee YM. Pathological angiogenesis and inflammation in tissues.
- 398 Archives of Pharmacal Research. 2021;44(1):1-15.
- 399 12. Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial
- 400 VEGF receptor signalling. Nature reviews Molecular cell biology. 2016;17(10):611-25.
- 401 13. Peach CJ, Mignone VW, Arruda MA, Alcobia DC, Hill SJ, Kilpatrick LE, et al.
- 402 Molecular pharmacology of VEGF-A isoforms: binding and signalling at VEGFR2. International
- 403 journal of molecular sciences. 2018;19(4):1264.
- 404 14. Albuquerque RJ, Hayashi T, Cho WG, Kleinman ME, Dridi S, Takeda A, et al.
- 405 Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous
- 406 inhibitor of lymphatic vessel growth. Nature medicine. 2009;15(9):1023-30.

It is made available under a CC-BY-NC-ND 4.0 International license .

407	15.	Uehara H. Ch	10 Y.	Cahoon J.	Archer B.	Ambati B. S	Splicing	shift from	membrane b	ound
107	10.	Containe 11, CI	10 1,	Cuntoon va	, include D.	1 millouti D. K	opnonig	Sinte nom	invitorane o	0 and

- 408 VEGF receptor 2 to soluble VEGFR2 using morpholino oligomer suppresses suture induced
- 409 corneal angiogenesis and lymphangiogenesis, and suppresses corneal graft rejection.
- 410 Investigative Ophthalmology & Visual Science. 2012;53(14):2406-.
- 411 16. Noma H, Funatsu H, Mimura T, Eguchi S. Vascular endothelial growth factor receptor-2
- 412 in macular oedema with retinal vein occlusion. Ophthalmic Research. 2012;48(1):56-8.
- 413 17. Noma H, Funatsu H, Mimura T, Eguchi S, Shimada K. Role of soluble vascular
- 414 endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusion.
- 415 British journal of ophthalmology. 2011;95(6):788-92.
- 416 18. Sanderson E, Glymour MM, Holmes MV, Kang H, Morrison J, Munafò MR, et al.
- 417 Mendelian randomization. Nature Reviews Methods Primers. 2022;2(1):6.
- 418 19. Schmidt AF, Finan C, Gordillo-Marañón M, Asselbergs FW, Freitag DF, Patel RS, et al.
- 419 Genetic drug target validation using Mendelian randomisation. Nature communications.

420 2020;11(1):3255.

- 421 20. Zuber V, Grinberg NF, Gill D, Manipur I, Slob EA, Patel A, et al. Combining evidence
- 422 from Mendelian randomization and colocalization: Review and comparison of approaches. The
- 423 American Journal of Human Genetics. 2022;109(5):767-82.
- 424 21. Evangelou E, Ioannidis JP. Meta-analysis methods for genome-wide association studies
 425 and beyond. Nature Reviews Genetics. 2013;14(6):379-89.
- 426 22. Bowden J, Holmes MV. Meta-analysis and Mendelian randomization: a review. Research
- 427 synthesis methods. 2019;10(4):486-96.
- 428 23. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al. Genomic atlas
- 429 of the human plasma proteome. Nature. 2018;558(7708):73-9.

- 430 24. Gudjonsson A, Gudmundsdottir V, Axelsson GT, Gudmundsson EF, Jonsson BG, Launer
- 431 LJ, et al. A genome-wide association study of serum proteins reveals shared loci with common
- 432 diseases. Nature communications. 2022;13(1):480.
- 433 25. Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrmisdottir
- 434 EL, et al. Large-scale integration of the plasma proteome with genetics and disease. Nature
- 435 genetics. 2021;53(12):1712-21.
- 436 26. Sun BB, Chiou J, Traylor M, Benner C, Hsu Y-H, Richardson TG, et al. Plasma
- 437 proteomic associations with genetics and health in the UK Biobank. Nature.
- 438 2023;622(7982):329-38.
- 439 27. Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, et al. FinnGen
- 440 provides genetic insights from a well-phenotyped isolated population. Nature.
- 441 2023;613(7944):508-18.
- 442 28. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide
- 443 association scans. Bioinformatics. 2010;26(17):2190-1.
- 444 29. Maintainer BP. liftOver: Changing genomic coordinate systems with rtracklayer::liftOver.
- 445 R package version 1.28.0, <u>https://www.bioconductor.org/help/workflows/liftOver/.2024</u>.
- 446 30. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation
- PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4(1):s13742-0150047-8.
- 449 31. Ochoa D, Hercules A, Carmona M, Suveges D, Baker J, Malangone C, et al. The next-
- 450 generation Open Targets Platform: reimagined, redesigned, rebuilt. Nucleic acids research.
- 451 2023;51(D1):D1353-D9.

It is made available under a CC-BY-NC-ND 4.0 International license .

452 32. Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the

453 deleteriousness of variants throughout the human genome. Nucleic acids research.

454 2019;47(D1):D886-D94.

- 455 33. Burgess S, Thompson SG, Collaboration CCG. Avoiding bias from weak instruments in
- 456 Mendelian randomization studies. International journal of epidemiology. 2011;40(3):755-64.

457 34. Skrivankova VW, Richmond RC, Woolf BA, Yarmolinsky J, Davies NM, Swanson SA, et

458 al. Strengthening the reporting of observational studies in epidemiology using Mendelian

459 randomization: the STROBE-MR statement. Jama. 2021;326(16):1614-21.

460 35. Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in

461 causal relationships inferred from Mendelian randomization between complex traits and

462 diseases. Nature genetics. 2018;50(5):693-8.

463 36. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with

464 multiple genetic variants using summarized data. Genetic epidemiology. 2013;37(7):658-65.

465 37. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid

466 instruments: effect estimation and bias detection through Egger regression. International journal

467 of epidemiology. 2015;44(2):512-25.

468 38. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity analyses for robust

469 causal inference from Mendelian randomization analyses with multiple genetic variants.

- 470 Epidemiology. 2017;28(1):30-42.
- 471 39. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between
- 472 imprecisely measured traits using GWAS summary data. PLoS genetics. 2017;13(11):e1007081.

473	40. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al.
474	Bayesian test for colocalisation between pairs of genetic association studies using summary
475	statistics. PLoS genetics. 2014;10(5):e1004383.
476	41. Liu B, Gloudemans MJ, Rao AS, Ingelsson E, Montgomery SB. Abundant associations
477	with gene expression complicate GWAS follow-up. Nature genetics. 2019;51(5):768-9.
478	42. Wang L-C, Hung K-H, Hsu C-C, Chen S-J, Li W-Y, Lin T-C. Assessment of retinal
479	pigment epithelial cells in epiretinal membrane formation. Journal of the Chinese Medical
480	Association. 2015;78(6):370-3.
481	43. Xu B, Zhou L, Chen Q, Zhang J, Huang L, Wang S, et al. Role of VEGFR2 in mediating
482	endoplasmic reticulum stress under glucose deprivation and determining cell death, oxidative
483	stress, and inflammatory factor expression. Frontiers in Cell and Developmental Biology.
484	2021;9:631413.
485	

It is made available under a CC-BY-NC-ND 4.0 International license .

496 Figure legends

- 497 Figure 1. Study design and datasets. sVEGFR2, soluble vascular endothelial growth factor
- 498 receptor 2; pQTL, protein quantitative trait loci; GWAS, genome-wide association studies; MR,
- 499 mendelian randomization; MR-PRESSO, MR Pleiotropy RESidual Sum and Outlier; LD, linkage
- 500 disequilibrium; SNP, single nucleotide polymorphism; Interval study, Sun BB. et al. 2018 Nature
- 501 (ref. 23); AGES study, Gudjonsson A. et al. 2022 Nature Communications (ref. 24); DECODE
- 502 study, Ferkingstad E. et al. 2021 Nature Genetics (ref. 25); UKB-PPP (UK Biobank Pharma
- 503 Proteomics Project) study, Sun BB. et al. 2023 Nature (ref. 26).
- 504
- 505
- 506
- 507
- 508
- 509
- 510
- 511
- 512

- 514
- 515
- 516
- 517

It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 2. Cis-MR results of IVW method for the effects of sVEGFR2 levels on macular

- pucker. Results were reported as odds ratio (OR) with 95% confidence interval (CI) per one-
- standard deviation increase in sVEGFR2 levels; statistical tests were two-tailed; P < 0.05 was
- considered significant; IVW, Inverse variance weighted; NSNP, number of single nucleotide
- polymorphism; Meta-analysis, combined data of Interval, AGES, and DECODE studies.

It is made available under a CC-BY-NC-ND 4.0 International license .

541 Figure 3. Colocalization of sVEGFR2 pQTL and macular pucker.

- 542 Bayesian colocalization analysis for sVEGFR2 pQTL from Interval (A), AGES (B), DECODE
- 543 (C), meta-analysis (D), and UKB-PPP (E) and macular pucker within \pm 100 kb around the
- *VEGFR2* gene (chromosome 4, position 55,078,481-55,125,595). A posterior probability of
- 545 hypothesis 4 (PPH₄) > 0.8 indicated strong evidence of colocalization. In the regional plots, each
- 546 dot represented a genetic variant, and the candidate causal variant was depicted as a purple
- 547 diamond. The color of other variants indicated their linkage disequilibrium (r²).

- - -

- 5.00

564	Supplementary figure 1. Q-Q plots and Manhattan plots of the sVEGFR2 pQTL. Mapped
565	genes for GWAS-wide significant variants ($P < 5 \times 10^{-8}$) in the Manhattan plot for the meta-
566	analysis of the three independent studies were shown.
567	
568	
569	
570	
571	
572	
573	
574	
575	
576	
577	
578	
579	
580	
581	
582	
583	
584	
585	
586	

587	Supplementary figure 2. Scatter plots and forest plots in cis-MR analysis. In scatter plots, the
588	x-axis shows the effect of each SNP on sVEGFR2 levels. The y-axis shows the effect of each
589	SNP on macular pucker (MP). The regression lines for inverse variance weighted (IVW),
590	weighted median, MR-egger, simple mode, weighted mode method are shown. In forest plots,
591	the x- axis shows the cis-MR effect size for sVEGFR2 levels on macular pucker. The y-axis
592	shows the analysis for each of the SNPs and for the SNPs in total using the MR-egger and IVW
593	methods. The data are presented as raw β values with corresponding 95% confidence intervals.
594	(A) Interval sVEGFR2 on MP; (B) AGES sVEGFR2 on MP; (C) DECODE sVEGFR2 on MP;
595	(D) Meta-analysis sVEGFR2 on MP; (E) UKB-PPP sVEGFR2 on MP.
596	
597	
598	
599	
600	
601	
602	
603	
604	
605	
606	
607	
608	

It is made available under a CC-BY-NC-ND 4.0 International license .

609 Supplementary figure 3. Leave-one-out plots of cis-MR analysis for the effect of sVEGFR2

- 610 levels on macular pucker. The x-axis shows the *cis* MR leave-one-out sensitivity analysis for
- 611 the effect of sVEGFR2 levels on macular pucker. The y-axis shows the analysis for leave-one-
- out of SNPs and the effect of the total SNPs on macular pucker. The data are presented as raw β
- 613 values with corresponding 95% confidence intervals.

- 1 -

- 631 Supplementary figure 4. Cis-MR analysis using IVW method for the effects of sVEGFR2
- 632 levels on other eye diseases. Results were reported as odds ratio (OR) with 95% confidence
- 633 interval (CI) per one-standard deviation increase in sVEGFR2 levels; statistical tests were two-
- tailed; P < 0.05 was considered significant; IVW, Inverse variance weighted; NSNP, number of
- 635 single nucleotide polymorphism; Meta-analysis, combined data of Interval, AGES, and
- 636 DECODE studies.

Protein measured by SomaScan

Protein measured by Olink

sVEGFR2 pQTL Interval study (n=3301)

sVEGFR2 pQTL AGES study (n=5361)

sVEGFR2 pQTL DECODE study (n=35559) **sVEGFR2 pQTL: Meta-analysis** of n=44221 individuals and >25M variants *cis*-SNPs associated with sVEGFR2

- P<5e-8;
- LD clumping R2=0.1 with 100kb window;
- ± 100 kb of *VEGFR2* gene;
- F-statistic>10

*cis-***MR**; Harmonization; MR-PRESSO; MR-Egger intercept; Cochran's Q; Reverse causality

Macular pucker (4599 cases and 413784 controls from FinnGen)

Colocalization (± 100kb of *VEGFR2* gene)

sVEGFR2 pQTL: from UKB-PPP study (n=33822 Europeans and > 20M variants)

- 30 GWAS significant loci (P<5e-8)
- 6 novel loci (outside of ± 500kb of loci in parental studies)

 4 novel loci after excluding loci of UKB-PPP study (outside of ± 500kb of reported loci)

sVEGFR2.levels	Outcome	NSNP		OR (95% CI)	Р
Interval	Macular pucker	3		0.88 (0.78 to 0.99)	3.0e-02
AGES		4		0.86 (0.73 to 1.01)	7.2e-02
DECODE		15	- -	0.84 (0.76 to 0.94)	1.8e-03
Meta-analysis		18	- - -	0.86 (0.77 to 0.95)	4.6e-03
UKB-PPP		16	- -	0.86 (0.78 to 0.96)	4.4e-03
		0.	.6 1 1. OR (95% C	2 I)	







sVEGFR2_pQTL - log₁₀(P)







200







Chromosome

























sVEGFR2.levels	Outcome	NSNP			OR (95% CI)	Ρ			
Meta-analysis	Macular hole	18		• <u>·</u>	0.89 (0.74 to 1.06)	0.19			
	Retinal detachments and breaks	18		- -	1.00 (0.95 to 1.05)	0.92			
	Diabetic retinopathy	18			0.96 (0.91 to 1.02)	0.18			
	Retinal vascular disorders	18			0.97 (0.89 to 1.06)	0.49			
	Retinal vascular occlusion	18		- = ¦-	0.96 (0.88 to 1.05)	0.33			
UKB-PPP	Macular hole	16			0.92 (0.78 to 1.09)	0.32			
	Retinal detachments and breaks	16		-	1.01 (0.97 to 1.06)	0.61			
	Diabetic retinopathy	16			0.97 (0.91 to 1.02)	0.23			
	Retinal vascular disorders	16		- 	1.01 (0.92 to 1.09)	0.89			
	Retinal vascular occlusion	16			0.99 (0.91 to 1.08)	0.87			
		0	6	1 1	2				
	OR (95% CI)								